In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody

AIMS: The oncostatin M (OSM) pathway drives fibrosis, inflammation and vasculopathy, and is a potential therapeutic target for inflammatory and fibrotic diseases. The aim of this first‐time‐in‐human experimental medicine study was to assess the safety, tolerability, pharmacokinetics and target engag...

Descripción completa

Detalles Bibliográficos
Autores principales: Reid, Juliet, Zamuner, Stefano, Edwards, Ken, Rumley, Sally‐Anne, Nevin, Katherine, Feeney, Maria, Zecchin, Chiara, Fernando, Disala, Wisniacki, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138480/
https://www.ncbi.nlm.nih.gov/pubmed/29900565
http://dx.doi.org/10.1111/bcp.13669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138480/
https://www.ncbi.nlm.nih.gov/pubmed/29900565
http://dx.doi.org/10.1111/bcp.13669

Ejemplares similares